Healthcare / BiotechnologyStockholm
$2.14
-0.13 (-6.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-5.6M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$17M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-22.7%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-7.0M · FCF $-7.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Net Income | $-7.0M | $-7.0M | $-7.6M | $-7.8M | — | $-9.6M |
| EBITDA | $-3.5M | $-3.5M | $-4.1M | $-4.5M | — | $-6.5M |
| EPS | -0.88 | -0.88 | -1.48 | -2.68 | — | -4.15 |
| Balance Sheet | ||||||
| Current Ratio | 5.46 | 5.46 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-7.8M | $-7.8M | $-5.5M | $-5.6M | — | $-21.2M |
| Returns | ||||||
| ROE | -22.7% | -22.7% | -25.1% | -29.5% | — | — |
| Valuation | ||||||
| P/B | 0.55 | 0.55 | 1.02 | 3.18 | 5.10 | — |
| Growth & Yield | ||||||
| EPS Growth | 40.7% | 40.7% | 44.6% | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-59.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.48 → -0.88
Residual
-59.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.